Avidity Biosciences Inc (RNA) Stock Price, Quote & News

Company Profile

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stag...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 401 7900

Website: www.aviditybiosciences.com

Address:

10578 Science Center Drive, Suite 125, San Diego, United States

highnihilism Oct. 5 at 6:08 AM

$RNA Avidity Biosciences (after hours volume) 48.25 +2.7% | volume 16k | market cap 6.9b

0 · Reply

Fairvalue10 Oct. 4 at 6:45 AM

$RNA How do you explain the move yesterday and the after hours trading ?

1 · Reply

savyaz Oct. 3 at 8:06 PM

$RNA Running AH

1 · Reply

wwmeinc Oct. 3 at 7:50 PM

$RNA ...ATH on $NVS today....over $257B M/C....lots of firepower, should they ever decide to be in the buying mood here....Avidity shareholders await ;) glta https://www.investing.com/equities/avidity-biosciences-inc

0 · Reply

Razgooz Oct. 3 at 7:15 PM

$RNA

0 · Reply

SweepCastApp Oct. 2 at 3:28 AM

$RNA: Unusual Options Activity Alerted CALL flow observed 150x contracts at Strike price of $45 Exp on 11/21/2025 with Premium of $61K and showing BULLISH Sentiment

0 · Reply

wwmeinc Oct. 1 at 10:45 PM

$RNA ....While we await(with patience of course)....FDA doors are close for now while the pol's try to hoodwink the taxpayers. Just something to consider. I see the potential for a buying opportunity again should some seller(s) appear trying to 'spook' some into selling early...just saying. Good trading and glta. As shutdown begins, FDA to stop accepting new drug submissions The funding lapse triggered by the U.S. government shutdown is the latest test for an agency that’s already dealt with significant layoffs and leadership upheaval this year. https://www.biopharmadive.com/news/fda-government-shutdown-new-drug-applications-reviews/761576/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202025-10-01%20BioPharma%20Dive:%20Commercialization%20%5Bissue:77381%5D&utm_term=BioPharma%20Dive:%20Commercialization

0 · Reply

johnnygogogo Oct. 1 at 6:23 PM

$RNA still think the Novartis deal rumor was a made up bedtime story courtesy of Leerink to sell their second(ary) secondary in a year. $SRPT / $ARWR data likely in Oct 7-11 window at WMS and they’re a Diamond Sponsor alongside Novartis. Avidity is a Bronze Sponsor, fwiw. https://www.wms2025.com/

1 · Reply

wwmeinc Oct. 1 at 4:01 PM

$RNA ...With the impending holiday at sunset today...vol. is just not showing up....Friday morning should give us(retailers only though) the real indication of who wants in and who just wants to f...k...around the shares...just some thoughts...glta https://www.stockwatch.com/Quote/Detail?U:RNA

0 · Reply

chickenwingww Oct. 1 at 1:36 PM

$RNA Looks like someone knows something.

1 · Reply

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 11, 2025, 7:56 PM EDT - 23 days ago

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

Sep 11, 2025, 2:36 PM EDT - 23 days ago

Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota

Sep 11, 2025, 8:08 AM EDT - 23 days ago

Lovesac, Avidity Biosciences, Veritone And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

LOVE VERI

Sep 10, 2025, 5:40 PM EDT - 24 days ago

Avidity Biosciences, Inc. (RNA) Discusses On Redefining The Treatment Of Duchenne Muscular Dystrophy (Transcript)

Sep 10, 2025, 4:01 PM EDT - 24 days ago

Avidity Biosciences Announces Proposed Public Offering of Common Stock

Sep 10, 2025, 7:00 AM EDT - 24 days ago

Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44

Sep 8, 2025, 4:45 PM EDT - 26 days ago

Avidity Biosciences, Inc. (RNA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 7, 2025, 10:15 PM EDT - 27 days ago

Avidity Biosciences, Inc. (RNA) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 5, 2025, 5:37 AM EDT - 4 weeks ago

Avidity Biosciences, Inc. (RNA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 27, 2025, 9:00 AM EDT - 5 weeks ago

Avidity Biosciences to Participate in Upcoming Investor Conferences

Aug 7, 2025, 4:05 PM EDT - 2 months ago

Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights

Aug 6, 2025, 11:41 AM EDT - 2 months ago

Novartis weighs deal for biotech Avidity Biosciences, FT reports

NVS

Jul 28, 2025, 9:00 AM EDT - 2 months ago

Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission

Jul 23, 2025, 9:00 AM EDT - 2 months ago

Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping

Jun 11, 2025, 9:00 AM EDT - 4 months ago

Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress

Jun 9, 2025, 7:01 AM EDT - 4 months ago

Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants

Jun 9, 2025, 7:00 AM EDT - 4 months ago

Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD

May 21, 2025, 4:05 PM EDT - 4 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 4:05 PM EDT - 5 months ago

Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights

May 6, 2025, 9:00 AM EDT - 5 months ago

Avidity Biosciences to Participate in Upcoming Investor Conference

Apr 8, 2025, 9:00 AM EDT - 6 months ago

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Mar 31, 2025, 9:00 AM EDT - 6 months ago

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy

Mar 17, 2025, 7:00 AM EDT - 7 months ago

Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial

Mar 12, 2025, 4:05 PM EDT - 7 months ago

Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 28, 2025, 9:00 AM EST - 7 months ago

Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases

Feb 27, 2025, 4:05 PM EST - 7 months ago

Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights

Jan 8, 2025, 9:00 AM EST - 9 months ago

Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025

Dec 11, 2024, 9:25 AM EST - 10 months ago

Avidity Biosciences Advances With FDA Clearance And Promising Data For Rare Diseases

Nov 12, 2024, 7:00 AM EST - 11 months ago

Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations

Nov 7, 2024, 4:05 PM EST - 11 months ago

Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights

Oct 31, 2024, 9:00 AM EDT - 1 year ago

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024

Sep 24, 2024, 2:15 PM EDT - 1 year ago

Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases

Sep 5, 2024, 9:00 AM EDT - 1 year ago

Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month

Aug 27, 2024, 9:30 AM EDT - 1 year ago

Life Science Cares San Diego Scales Partnership with Avidity Biosciences Through Life Science Shares Program

Aug 19, 2024, 9:00 AM EDT - 1 year ago

Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Aug 16, 2024, 3:21 PM EDT - 1 year ago

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Aug 9, 2024, 4:05 PM EDT - 1 year ago

Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights

Aug 5, 2024, 9:00 AM EDT - 1 year ago

Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer

Jun 24, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

CTNM

Jun 20, 2024, 9:00 AM EDT - 1 year ago

Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day

Jun 13, 2024, 8:00 PM EDT - 1 year ago

Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock

Jun 12, 2024, 4:01 PM EDT - 1 year ago

Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock

Jun 12, 2024, 10:15 AM EDT - 1 year ago

Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday

CASY RTO

May 19, 2024, 11:23 AM EDT - 1 year ago

Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline

May 15, 2024, 9:00 AM EDT - 1 year ago

Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors

May 9, 2024, 4:05 PM EDT - 1 year ago

Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

Feb 29, 2024, 1:39 PM EST - 1 year ago

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Feb 29, 2024, 12:00 PM EST - 1 year ago

Avidity Biosciences Honors Rare Disease Day®

Feb 29, 2024, 7:00 AM EST - 1 year ago

Avidity Biosciences Announces Oversubscribed $400 Million Private Placement

highnihilism Oct. 5 at 6:08 AM

$RNA Avidity Biosciences (after hours volume) 48.25 +2.7% | volume 16k | market cap 6.9b

0 · Reply

Fairvalue10 Oct. 4 at 6:45 AM

$RNA How do you explain the move yesterday and the after hours trading ?

1 · Reply

savyaz Oct. 3 at 8:06 PM

$RNA Running AH

1 · Reply

wwmeinc Oct. 3 at 7:50 PM

0 · Reply

Razgooz Oct. 3 at 7:15 PM

$RNA

0 · Reply

SweepCastApp Oct. 2 at 3:28 AM

$RNA: Unusual Options Activity Alerted CALL flow observed 150x contracts at Strike price of $45 Exp on 11/21/2025 with Premium of $61K and showing BULLISH Sentiment

0 · Reply

wwmeinc Oct. 1 at 10:45 PM

0 · Reply

johnnygogogo Oct. 1 at 6:23 PM

1 · Reply

wwmeinc Oct. 1 at 4:01 PM

0 · Reply

chickenwingww Oct. 1 at 1:36 PM

$RNA Looks like someone knows something.

1 · Reply

chickenwingww Oct. 1 at 1:36 PM

$RNA Deal back on?!?

0 · Reply

Jhane13 Sep. 30 at 7:35 PM

$RNA Congratulations to all the longs.

0 · Reply

wwmeinc Sep. 30 at 5:34 PM

$RNA ...I 'trust' you and your friends and family and colleagues all bought a tonne of call options or shares, to pave the way, towards yours and theirs retirement...it would be the only 'normal' procedure to make with your insight/knowledge of the situation....just saying...looking forward to reading all about you and your friends option play in the WSJ or Reuters or FT.com or failing all those...the justice.gov....By chance, just by chance though, do you have the confirmation link to your post? Thanks. glta

4 · Reply

Jhane13 Sep. 30 at 2:57 PM

$RNA Company is sold.

3 · Reply

highnihilism Sep. 30 at 8:25 AM

$MPLX MPLX LP Units: 361 trades, $269K vs $239K avg (1.12x). $173K calls / $96K puts. $SVIX -1X Short Vix Futures ETF: 760 trades, $295K vs $553K avg (0.53x). $172K calls / $123K puts. $ALIT Alight: 331 trades, $197K vs $110K avg (1.80x 🚨). $171K calls / $26K puts. $RNA Avidity Biosciences: 125 trades, $267K vs $936K avg (0.28x). $171K calls / $96K puts.

0 · Reply

Jhane13 Sep. 29 at 7:42 PM

$RNA Congratulations longs.

0 · Reply

_www_larval_com_ Sep. 29 at 5:48 PM

$RNA has turned 5% higher to -3% (~2Mv) in the last few minutes, 10/17 options, follow for more volatility.

0 · Reply

Fairvalue10 Sep. 29 at 5:21 PM

$RNA ?? any idea ?

2 · Reply

wwmeinc Sep. 29 at 2:18 PM

$RNA ....Good read from last wk...in case some missed it...bodes very well for the patients and shareholders as this FDA seems very, very focused on great results only....I'am still waiting though for the BLA though....gotta keep all points front and center....while holding for the pay-off!....glta https://www.insideprecisionmedicine.com/topics/precision-medicine/the-boys-avidity-biosciences-dmd-rna-therapy-reverses-disease-progression/

0 · Reply

perchedcats Sep. 25 at 12:15 PM

$PEPG let’s keep things in perspective: $RNA valued $6.3B - that’s Billion…

0 · Reply

perchedcats Sep. 24 at 11:31 PM

$PEPG $RNA market cap $6B …. PEPG can keep climbing as the data validated their delivery tech

0 · Reply

wwmeinc Sep. 24 at 3:05 PM

$RNA ......just looking around the gene space as usual....the $QURE news in particular today...glta "Application: AMT-130 is specifically for Huntington's disease, while Avidity's AOC platform is a broader approach for delivering oligonucleotides to various tissues and disease" https://investingnews.com/daily/life-science-investing/genetics-investing/top-nasdaq-genetic-stocks/

0 · Reply

Market Cap	6.86B
Revenue (ttm)	10.90M
Net Income (ttm)	-322.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,956.88%
Debt to Equity Ratio	0.00

Volume	1,461,400
Avg Vol	3,585,158
Day's Range	N/A - N/A
Shares Out	145.90M
Stochastic %K	96%
Beta	0.97
Analysts	Strong Sell
Price Target	$68.31